Compare MYGN & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | BDSX |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 276.2M |
| IPO Year | 1996 | 2020 |
| Metric | MYGN | BDSX |
|---|---|---|
| Price | $4.00 | $28.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $7.64 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 1.9M | 88.8K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $771,400,000.00 | $88,499,000.00 |
| Revenue This Year | $6.86 | $25.26 |
| Revenue Next Year | $5.45 | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.33 | ★ 24.08 |
| 52 Week Low | $2.74 | $5.26 |
| 52 Week High | $8.59 | $31.31 |
| Indicator | MYGN | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 57.31 |
| Support Level | $2.89 | $19.26 |
| Resistance Level | $5.42 | $31.31 |
| Average True Range (ATR) | 0.24 | 1.67 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 85.20 | 68.92 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.